lomustine has been researched along with Necrosis in 6 studies
Necrosis: The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Imaging necrosis on MRI scans was assessed and compared to outcome measures of the European Organisation for Research and Treatment of Cancer 26101 phase III trial that compared single-agent lomustine with lomustine plus bevacizumab in patients with progressive glioblastoma." | 3.91 | Imaging necrosis during treatment is associated with worse survival in EORTC 26101 study. ( Bendszus, M; Brandes, AA; Bromberg, JEC; Campone, M; Clement, PM; Domont, J; Fabbro, M; Golfinopoulos, V; Gorlia, T; Harting, I; Idbaih, A; Kickingereder, P; Le Rhun, E; Nowosielski, M; Platten, M; Sahm, F; Taal, W; Taphoorn, MJB; van den Bent, MJ; Weller, M; Wick, W, 2019) |
| "AOA tumors with necrosis are to be considered WHO grade IV tumors (GBM)." | 2.74 | Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951. ( Allgeier, A; Brandes, AA; Bromberg, JE; Gorlia, T; Grisold, W; Ibdaih, A; Kouwenhoven, MC; Kros, JM; Lacombe, D; Mirimanoff, R; Mokhtari, K; Sipos, L; Teepen, JL; van den Bent, MJ; van Duinen, SG; Vandenbos, F; Vecht, CJ; Wesseling, P, 2009) |
| " The radiation dose ranged from 3000 to 4650 rad and the oral CCNU dosage from 300 mg to 1050 mg." | 1.27 | Sudden onset of blindness in patients treated with oral CCNU and low-dose cranial irradiation. ( Kleinschmidt-Demasters, BK; Perez, GM; Wilson, WB, 1987) |
| " The depression of platelets and white blood cells was mild after a single dosage of 40 mg/kg CCNU which recovered on about the 6th day." | 1.26 | Brain tumor chemotherapy using a rat glioma model. ( Mennel, HD; Tamura, M; Zülch, KJ, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (33.33) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nowosielski, M | 1 |
| Gorlia, T | 2 |
| Bromberg, JEC | 1 |
| Sahm, F | 1 |
| Harting, I | 1 |
| Kickingereder, P | 1 |
| Brandes, AA | 2 |
| Taphoorn, MJB | 1 |
| Taal, W | 1 |
| Domont, J | 1 |
| Idbaih, A | 1 |
| Campone, M | 1 |
| Clement, PM | 1 |
| Weller, M | 1 |
| Fabbro, M | 1 |
| Le Rhun, E | 1 |
| Platten, M | 1 |
| Golfinopoulos, V | 1 |
| van den Bent, MJ | 2 |
| Bendszus, M | 1 |
| Wick, W | 1 |
| Kouwenhoven, MC | 1 |
| Kros, JM | 1 |
| Ibdaih, A | 1 |
| Bromberg, JE | 1 |
| Mokhtari, K | 1 |
| van Duinen, SG | 1 |
| Teepen, JL | 1 |
| Wesseling, P | 1 |
| Vandenbos, F | 1 |
| Grisold, W | 1 |
| Sipos, L | 1 |
| Mirimanoff, R | 1 |
| Vecht, CJ | 1 |
| Allgeier, A | 1 |
| Lacombe, D | 1 |
| Sobol, RE | 1 |
| Fakhrai, H | 1 |
| Shawler, D | 1 |
| Gjerset, R | 1 |
| Dorigo, O | 1 |
| Carson, C | 1 |
| Khaleghi, T | 1 |
| Koziol, J | 1 |
| Shiftan, TA | 1 |
| Royston, I | 1 |
| Tamura, M | 1 |
| Mennel, HD | 1 |
| Zülch, KJ | 1 |
| Fulton, DS | 1 |
| Urtasun, RC | 1 |
| Scott-Brown, I | 1 |
| Johnson, ES | 1 |
| Mielke, B | 1 |
| Curry, B | 1 |
| Huyser-Wierenga, D | 1 |
| Hanson, J | 1 |
| Feldstein, M | 1 |
| Wilson, WB | 1 |
| Perez, GM | 1 |
| Kleinschmidt-Demasters, BK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| PHASE III STUDY OF ADJUVANT PROCARBAZINE, CCNU AND VINCRISTINE CHEMOTHERAPY IN PATIENTS WITH HIGHLY ANAPLASTIC OLIGODENDROGLIOMA[NCT00002840] | Phase 3 | 350 participants (Anticipated) | Interventional | 1996-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for lomustine and Necrosis
| Article | Year |
|---|---|
Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Cell Proliferation; Ch | 2009 |
Increasing radiation dose intensity using hyperfractionation in patients with malignant glioma. Final report of a prospective phase I-II dose response study.
Topics: Adolescent; Adult; Age Factors; Aged; Astrocytoma; Brain; Brain Neoplasms; Cobalt Radioisotopes; Com | 1992 |
4 other studies available for lomustine and Necrosis
| Article | Year |
|---|---|
Imaging necrosis during treatment is associated with worse survival in EORTC 26101 study.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Clinical T | 2019 |
Interleukin-2 gene therapy in a patient with glioblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cells, Cultured; Combined Modality | 1995 |
Brain tumor chemotherapy using a rat glioma model.
Topics: Animals; Bone Marrow; Brain Neoplasms; Cell Nucleus; Disease Models, Animal; Dose-Response Relations | 1979 |
Sudden onset of blindness in patients treated with oral CCNU and low-dose cranial irradiation.
Topics: Administration, Oral; Aged; Blindness; Brain; Brain Neoplasms; Carcinoma, Small Cell; Combined Modal | 1987 |